MedMira (MedMira) Accounts Receivable : $0.97 Mil (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. MedMira's accounts receivables for the quarter that ended in Jan. 2024 was $0.97 Mil.

Accounts receivable can be measured by Days Sales Outstanding. MedMira's Days Sales Outstanding for the quarter that ended in Jan. 2024 was 794.94.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. MedMira's Net-Net Working Capital per share for the quarter that ended in Jan. 2024 was $-0.02.

MedMira Accounts Receivable Historical Data

The historical data trend for MedMira's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Accounts Receivable Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Accounts Receivable

Get a 7-Day Free Trial

0.03

0.15

1.00

0.97

0.96

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Accounts Receivable	Get a 7-Day Free Trial															0.97	1.00	0.96	1.01	0.97

MedMira Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

MedMira Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

MedMira's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.967	/	0.111	*	91
=	794.94

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), MedMira's accounts receivable are only considered to be worth 75% of book value:

MedMira's Net-Net Working Capital Per Share for the quarter that ended in Jan. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.636	+	0.75 * 0.967	+	0.5 * 0.158	-	15.307
-	0.002	-	0)	/	701.731
=	-0.02

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

MedMira Accounts Receivable Related Terms

Thank you for viewing the detailed overview of MedMira's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.